JAK2 and myeloproliferative neoplasm: However, results from clinical experience suggest targeting JAK2 may not be sufficient or even the best option to reverse the course of disease in MPN patients, and a plethora of pre-clinical studies have suggested a potential benefit of therapeutic combinations.